Abstract
Diabetes is on the increase worldwide and greater than 90% are type 2. There are two features to type 2 diabetes: muscle, fat and liver tissues are insulin resistant and β cells lose the ability to secrete insulin. Prior to developing diabetes, however, insulin resistant individuals lose the first-phase insulin secretion response. Transgenic mice lacking insulin receptors in their β cells have no first-phase response. Primary cultures of mouse islets pre-exposed to anti-insulin do not exhibit a first-phase insulin secretion response. That is, β cells, like muscle, fat, and liver, are an insulin sensitive tissue and in the presence of insulin resistance (type 2 diabetes), in the absence of insulin receptors (transgenic mice lacking β cell insulin receptors), or in the absence of constitutively secreted insulin (anti-insulin treatment), β cells are unable to respond properly to post-prandial glucose. The purpose of this report is to review our understanding of the glucose-stimulus response and of insulin signaling, and to suggest why the latter may be necessary for the former to proceed.
Keywords: insulin signaling, islet glucose oxidation, pyruvate dehydrogenase, glucokinase, anti-insulin inhibition of insulin secretion, b cell communication, constitutively secreted insulin
Current Diabetes Reviews
Title: Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells
Volume: 1 Issue: 3
Author(s): H. J. Goren
Affiliation:
Keywords: insulin signaling, islet glucose oxidation, pyruvate dehydrogenase, glucokinase, anti-insulin inhibition of insulin secretion, b cell communication, constitutively secreted insulin
Abstract: Diabetes is on the increase worldwide and greater than 90% are type 2. There are two features to type 2 diabetes: muscle, fat and liver tissues are insulin resistant and β cells lose the ability to secrete insulin. Prior to developing diabetes, however, insulin resistant individuals lose the first-phase insulin secretion response. Transgenic mice lacking insulin receptors in their β cells have no first-phase response. Primary cultures of mouse islets pre-exposed to anti-insulin do not exhibit a first-phase insulin secretion response. That is, β cells, like muscle, fat, and liver, are an insulin sensitive tissue and in the presence of insulin resistance (type 2 diabetes), in the absence of insulin receptors (transgenic mice lacking β cell insulin receptors), or in the absence of constitutively secreted insulin (anti-insulin treatment), β cells are unable to respond properly to post-prandial glucose. The purpose of this report is to review our understanding of the glucose-stimulus response and of insulin signaling, and to suggest why the latter may be necessary for the former to proceed.
Export Options
About this article
Cite this article as:
Goren J. H., Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells, Current Diabetes Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339905774574301
DOI https://dx.doi.org/10.2174/157339905774574301 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identifying Knowledge Deficits of Food Insecure Patients with Diabetes
Current Diabetes Reviews Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study
Current Alzheimer Research Inhibitory Effect of Phenolic Extracts of Four Algerian Atlas Saharan Plants on α-Glucosidase Activity
Current Enzyme Inhibition A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
Current Genomics Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Patent Perspective for Potential Antioxidant Compounds-Rutin and Quercetin
Recent Patents on Nanomedicine Soybean and Processed Soy Foods Ingredients, and Their Role in Cardiometabolic Risk Prevention
Recent Patents on Food, Nutrition & Agriculture Injectable Thermosensitive Chitosan/Glycerophosphate-Based Hydrogels for Tissue Engineering and Drug Delivery Applications: A Review
Recent Patents on Drug Delivery & Formulation A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
Current Neuropharmacology Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury
Current Alzheimer Research Regulation of Insulin Release at Pre-exocytotic Stages of the Secretory Process
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Current Medicinal Chemistry Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Vascular Endothelial Dysfunction and Nutritional Compounds in Early Type 1 Diabetes
Current Diabetes Reviews Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism Promising Recent Regenerative Medicine Patents in Plastic and Reconstructive Surgery: Nanotechnology, Structural Fat Grafting, Bone Repair and Regeneration, and Microvascular Surgery
Recent Patents on Regenerative Medicine Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism The Stomach as an Energy Homeostasis Regulating Center. An Approach for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery